Study on the penetration ability of brigatinib into the brain

Brigatinib is a targeted therapy drug, specifically an anaplastic lymphoma kinase (ALK) inhibitor. This drug plays an important role in treating certain types of cancer, particularly those with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Brigatinib, also known asBrigatinib, is an oral, small molecule tyrosine kinase inhibitor. It mainly targets the inhibition of anaplastic lymphoma kinase (ALK), which is an important therapeutic target in NSCLC. Brigatinib can bind to the ALK protein, thereby blocking its signal transduction pathway and inhibiting the growth and proliferation of tumor cells.

Brigatinib is mainly used to treat ALKpositive locally advanced or metastatic NSCLC. In clinical trials, brigatinib has demonstrated significant efficacy, effectively prolonging patients' progression-free survival and improving objective response rates. Particularly for patients whose disease has progressed despite prior treatment with crizotinib, brigatinib provides an effective treatment option.

In terms of safety, brigatinib also performed relatively well. Although some adverse reactions may occur during use, most reactions are mild to moderate and can be alleviated with appropriate symptomatic treatment. In addition, brigatinib also demonstrated good tolerability, allowing patients to continue receiving treatment.

Brigatinib has a unique dimethylphosphorus oxide (DMPO) structure, which enhances its binding force to ALK protein, thereby improving drug activity. In addition, brigatinib can also broadly inhibit a variety of ALK fusion types and drug-resistant mutations, showing good efficacy and safety. These characteristics make brigatinib play an important role in the treatment of NSCLC.

References:

https://www.mdpi.com/1999-4923/13/9/1446